Reopia Optics’ key highlights include: • The number of myopes globally will increase to 5 billion by 2050, with 1 billion of these being high myopes at risk for blinding complications. • Reopia Optics believes the best way to avert this worldwide epidemic is to intervene early. o The company is developing proprietary spectacle mounted optics that are designed to be worn by children (5-12 years old) who are experiencing emerging myopia. o The expected result is prevention of further eye growth that leads to myopia and associated complications. • Our patent portfolio is strong, with 2 applications filed including in the PCT for global coverage. • The value proposition and customer profile has been validated through completion of a regional NSF funded iCorps program, and the proprietary technology has been positively vetted under NDA by some of the largest global strategics in this space. • The company is raising up to $1M of equity capital for optimization of our optical design, and to obtain pre-clinical proof-of-concept data.